Tianshui Zhongxing Bio-technology Co (002772) Fair Value & Analysis
Consumer Defensive · CN · Market cap 4.9B CNY
Fair value as of: Jul 22, 2026
From 17 valuation models · updated 19 days ago
Fair value updated Jul 22, 2026, revised from ¥16.41 to ¥8.82 (−46.3%) since Jun 25, 2026. Share price −15.3% over the past month.
A solid business, but screening 18% overvalued on our models.
What matters now
- Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder.
- Our model range runs from ¥6.58 (bear) to ¥11.02 (bull), base ¥8.82. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 62/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range ¥5.22 – ¥19.19 · fair‑value band ¥6.58 – ¥11.02 · the ¥10.70 price screens above the ¥8.82 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Tianshui Zhongxing Bio-technology Co (002772) currently trades at ¥10.70, while our model-based Fair Value estimate is ¥8.82, implying the stock looks roughly 17.6% overvalued today. The Quality Score stands at 62/100 (solid quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Tianshui Zhongxing Bio-technology Co generated revenue of 2.2B CNY at a net margin of 20.2%. Revenue grew 27.4% year over year. It earns a return on equity of 12.9%. Net debt stands at 1.4B CNY. Fundamentals as of Jul 22, 2026
Our scenario range runs from ¥6.58 (bear case) to ¥11.02 (bull case); at ¥10.70, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 45% below its 52-week high and 47% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at 102% fair-value upside, at -18%, 002772 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 17 models by family
Widest divergence: Growth Earnings (¥22.63) versus DCF Models (¥1.89). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 41
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Tianshui Zhongxing Bio-technology Co.,Ltd., together with its subsidiaries, engages in the research and development, production and sales of edible mushrooms in China and internationally. It offers enoki and button mushrooms; cordyceps militaris; and cordyceps sinensis.
Full company description
Tianshui Zhongxing Bio-technology Co.,Ltd., together with its subsidiaries, engages in the research and development, production and sales of edible mushrooms in China and internationally. It offers enoki and button mushrooms; cordyceps militaris; and cordyceps sinensis. The company also engages in agriculture planting, investment management, and real estate development businesses. Tianshui Zhongxing Bio-technology Co.,Ltd. was founded in 2005 and is headquartered in Tianshui, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Tianshui Zhongxing Bio-technology Co reported revenue of ¥2.1B in FY2025 versus ¥1.6B in FY2021, a compound +7.8%/yr. Reported net income was ¥335M in FY2025, compounding +57.1%/yr from FY2021.
002772 screens 18% overvalued. Compare with Muyuan Foods Group →
Peer Group
Farm Products · 291 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Farm Products median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Farm Products stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Muyuan Foods Group 002714 | ¥40.90 | ¥48.19 | +18% |
| Wens Foodstuff Group 300498 | ¥14.51 | ¥12.08 | -17% |
| Mowi ASA MOWI | kr 188.40 | kr 262.59 | +39% |
| PT Charoen Pokphand Indonesia Tbk, CPIN | 3,120 IDR | 7,076 IDR | +127% |
| Charoen Pokphand Foods Public Company CPF | 22.00 THB | 55.71 THB | +153% |
| PT Triputra Agro Persada Tbk TAPG | 1,540 IDR | 3,105 IDR | +102% |
| PT FAP Agri Tbk FAPA | 7,300 IDR | 7,463 IDR | +2% |
| PT Japfa Comfeed Indonesia Tbk JPFA | 2,070 IDR | 7,231 IDR | +249% |
| Thaifoods Group TFGR | 10.60 THB | 23.53 THB | +122% |
| PT Jhonlin Agro Raya Tbk JARR | 1,845 IDR | 610.80 IDR | -67% |
Compare Tianshui Zhongxing Bio-technology Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Tianshui Zhongxing Bio-technology Co (002772) overvalued or undervalued?
What is the fair value of 002772?
What is the quality score of 002772?
What is the revenue of Tianshui Zhongxing Bio-technology Co (002772)?
What is the net profit margin of 002772?
Does Tianshui Zhongxing Bio-technology Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Tianshui Zhongxing Bio-technology Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.